Tags

Type your tag names separated by a space and hit enter

Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.
J Clin Endocrinol Metab. 2011 Feb; 96(2):273-88.JC

Abstract

OBJECTIVE

The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia.

PARTICIPANTS

The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer.

EVIDENCE

This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence.

CONSENSUS PROCESS

One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines.

CONCLUSIONS

Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.

Authors+Show Affiliations

Cedars Sinai Medical Center, Los Angeles, California 90048, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Guideline
Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

21296991

Citation

Melmed, Shlomo, et al. "Diagnosis and Treatment of Hyperprolactinemia: an Endocrine Society Clinical Practice Guideline." The Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 2, 2011, pp. 273-88.
Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-88.
Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. (2011). Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism, 96(2), 273-88. https://doi.org/10.1210/jc.2010-1692
Melmed S, et al. Diagnosis and Treatment of Hyperprolactinemia: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(2):273-88. PubMed PMID: 21296991.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. AU - Melmed,Shlomo, AU - Casanueva,Felipe F, AU - Hoffman,Andrew R, AU - Kleinberg,David L, AU - Montori,Victor M, AU - Schlechte,Janet A, AU - Wass,John A H, AU - ,, PY - 2011/2/8/entrez PY - 2011/2/8/pubmed PY - 2011/3/22/medline SP - 273 EP - 88 JF - The Journal of clinical endocrinology and metabolism JO - J Clin Endocrinol Metab VL - 96 IS - 2 N2 - OBJECTIVE: The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia. PARTICIPANTS: The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines. CONCLUSIONS: Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented. SN - 1945-7197 UR - https://www.unboundmedicine.com/medline/citation/21296991/Diagnosis_and_treatment_of_hyperprolactinemia:_an_Endocrine_Society_clinical_practice_guideline_ L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2010-1692 DB - PRIME DP - Unbound Medicine ER -